News | December 20, 2011

Adult Stem Cell Patients Continue to See Cardiac Improvement Years After Treatment

 

December 20, 2011 –– Howie Lindeman was facing the loss of his career and Neim Malo wasn’t supposed to see 2011. They were each treated for heart disease years ago using their own stem cells to repair their damaged heart tissue. Several years following treatment from Regenocyte, both men continue to see improvement in their condition and quality of life.

Howie Lindeman, 60, had a heart attack at 39 years old that severely damaged his heart. He went through several procedures including having stents placed in his arteries and his physicians were considering open-heart surgery for a quintuple bypass. He was in constant pain and struggled to walk just 25 feet, but when Zannos G. Grekos, M.D., MAAC, FACC, chief medical officer of Regenocyte and a Florida-based pioneer in the field of adult stem cell therapy suggested he have the Regenocyte adult stem cell procedure, he jumped at the opportunity. A normal ejection fraction (EF) is over 50 percent and Lindeman’s was down to a dangerous 22 percent before the adult stem cell procedure. Shortly after receiving treatment, his EF improved to a near-normal 47 percent, and is now at a stable 54 percent.

Neim Malo, 54, suffered a heart attack at 47 years old. He had three stents put in and was told by doctors that he would only live five more years. He refused to accept such a grim fate, so he searched for alternative treatment and found adult stem cell therapy. Malo’s EF was at 28 percent when he received adult stem cell treatment in 2006 and since then, his heart function has improved to 50 percent.

“I have more energy than ever,” said Malo. “You can still find me in my restaurant everyday outpacing people half my age. I’ve lived beyond those five years and will continue to prove my former doctors wrong.”

Lindeman and Malo now participate in Regenocyte seminars to share their experiences with attendees who are considering the treatment for themselves or their loved ones. In his presentation about the Regenocyte procedure, Grekos describes how blood is extracted from the patient and sent on to a laboratory where the patient’s stem cells are removed.

“The lab provides a key step in the Regenocyte process,” Grekos explained. “The lab extracts the stem cells from the blood and activates them into millions of adult stem cells while ‘educating’ them to assist the exact organ that needs treatment.”

About a week after the blood arrives at the laboratory, the adult stem cells are shipped to a hospital at an international location and the patient has already been admitted.

In this groundbreaking treatment, cardiologist inserted a catheter into Lindeman and Malo’s hearts. Over the next 20 minutes, about 30 separate injections of adult stem cells were introduced into the damaged part of their hearts. The process of tissue repair began almost immediately.

Patients remain in the hospital overnight for observation, and are typically discharged the next day. Grekos continues to have regular appointments with patients to monitor their progress and measure their results.

“We continue to see remarkable results from adult stem cell treatment,” said Grekos. “Successes like those we’ve seen with Howie and Neim are not uncommon and show significant promise for diseases in other organs.”

“I have a high-stress, high-energy job that I absolutely love,” says Lindeman. “The Regenocyte adult stem cell treatment has allowed me to continue my career and enjoy the active lifestyle I thought I had lost for good. I’m a new person and I continue to feel better every day.”

Grekos and the Regenocyte medical team continue to research the impact of adult stem cell therapy on heart disease.

For more information: www.regenocyte.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init